<table border="1" id="t22025830" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 1: Clinically Significant Drug Interactions with MS
CONTIN</caption>
<colgroup>
<col width="13*"></col>
<col width="86*"></col>
</colgroup>
<tbody>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Benzodiazepines
and Other Central Nervous System (CNS) Depressants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Clinical
Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Due to additive pharmacologic
effect, the concomitant use of benzodiazepines or other CNS depressants,
including alcohol, can increase the risk of hypotension, respiratory
depression, profound sedation, coma, and death.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Reserve concomitant prescribing
of these drugs for use in patients for whom alternative treatment
options are inadequate. Limit dosages and durations to the minimum
required. Follow patients closely for signs of respiratory depression
and sedation  <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#Section_5.4">5.4</linkhtml>)]</content>.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Benzodiazepines and other sedative
hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics,
antipsychotics, other opioids, alcohol.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Serotonergic
Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Clinical
Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">The concomitant use of opioids
with other drugs that affect the serotonergic neurotransmitter system
has resulted in serotonin syndrome.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">If concomitant use is warranted,
carefully observe the patient, particularly during treatment initiation
and dose adjustment. Discontinue MS CONTIN if serotonin syndrome is
suspected.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Selective serotonin reuptake
inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors
(SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor
antagonists, drugs that effect the serotonin neurotransmitter system
(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO)
inhibitors (those intended to treat psychiatric disorders and also
others, such as linezolid and intravenous methylene blue).</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Monoamine
Oxidase Inhibitors (MAOIs)</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Clinical
Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">MAOI interactions with opioids
may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory
depression, coma) <content stylecode="italics">[see Warnings and Precautions (5.6)].</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Do not use MS CONTIN in patients
taking MAOIs or within 14 days of stopping such treatment.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">phenelzine, tranylcypromine,
linezolid</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Mixed Agonist/Antagonist
and Partial Agonist Opioid Analgesics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Clinical
Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">May reduce the analgesic effect
of MS CONTIN and/or precipitate withdrawal symptoms.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Avoid concomitant use.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">butorphanol, nalbuphine, pentazocine,
buprenorphine</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Muscle Relaxants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Clinical
Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Morphine may enhance the neuromuscular
blocking action of skeletal muscle relaxants and produce an increased
degree of respiratory depression.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Monitor patients for signs of
respiratory depression that may be greater than otherwise expected
and decrease the dosage of MS CONTIN and/or the muscle relaxant as
necessary.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Cimetidine</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Clinical
Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">The concomitant use of cimetidine
can potentiate morphine effects and increase risk of hypotension,
respiratory depression, profound sedation, coma, and death.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Monitor patients for signs of
respiratory depression that may be greater than otherwise expected
and decrease the dosage of MS CONTIN and/or cimetidine as necessary.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Clinical
Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Opioids can reduce the efficacy
of diuretics by inducing the release of antidiuretic hormone.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Monitor patients for signs of
diminished diuresis and/or effects on blood pressure and increase
the dosage of the diuretic as needed.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Anticholinergic
Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Clinical
Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">The concomitant use of anticholinergic
drugs may increase risk of urinary retention and/or severe constipation,
which may lead to paralytic ileus.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Monitor patients for signs of
urinary retention or reduced gastric motility when MS CONTIN is used
concomitantly with anticholinergic drugs.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">P-Glycoprotein
(P-gp) Inhibitors</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Clinical
Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">The concomitant use of PGP-inhibitors
can increase the exposure to morphine by about two-fold and can increase
risk of hypotension, respiratory depression, profound sedation, coma,
and death.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Monitor patients for signs of
respiratory depression that may be greater than otherwise expected
and decrease the dosage of MS CONTIN and/or the PGP-inhibitor as necessary.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="italics">Example:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Quinidine</td>
</tr>
</tbody>
</table>